Regulatory Shifting Gears: TGA Releases Consultation on Overhauling Australian Sunscreen Oversight

On March 26, 2026, the Australian Therapeutic Goods Administration (TGA) published a comprehensive notice titled “Seeking to Improve the Regulation of Sunscreens in Australia.” This 8-week public consultation stems from Australia’s persistently high incidence of skin cancer and targets deep-seated loopholes in the current oversight framework.

Stakeholders must submit their feedback by May 23, 2026. Additionally, a public webinar will be hosted on April 14, 2026, at 1:00 PM (AEST) featuring an expert panel Q&A session to dissect the critical proposals.

I. Strategic Context and Drivers for Reform

1. Current Regulatory Landscape

Australia categorizes sunscreens into two distinct streams based on their primary function:

• Therapeutic Sunscreens: Regulated as listed medicines under the TGA. They must be enrolled in the Australian Register of Therapeutic Goods (ARTG) and are subjected strictly to post-market monitoring.
• Cosmetic Sunscreens: Partially exempted from therapeutic goods laws. Ingredient safety falls under the Australian Industrial Chemicals Introduction Scheme (AICIS), while labelling claims are overseen by the Australian Competition and Consumer Commission (ACCC).
• Core Standards: Both streams utilize the AS/NZS 2604:2021 standard alongside related ISO testing methods.

2. Core Drivers for the 2026 Reform

• Domestic Scandals: A damning 2025 report by consumer group CHOICE revealed that out of 20 tested sunscreens claiming SPF 50/50+, 18 failed to meet their claims, with one dropping as low as SPF 4. Separately, an ABC investigation discovered multiple commercial products riding on identical ARTG registration numbers, severely damaging public trust.
• International Alignment: Ongoing safety scrutiny of UV filters by the US FDA and the 2024 publication of new ISO in vitro SPF testing methodologies have pressured Australia to update its rules.
• Systemic Vulnerabilities: The existing framework suffers from high intra-laboratory variability in in vivo testing, poor oversight of testing laboratories, a lack of mandatory finished-product testing, and chaotic high-SPF claims on cosmetic products.

II. Scope of the Consultation

• In-Scope Items: In vivo/in vitro SPF testing protocols, laboratory accreditation models, mandatory data submission workflows, finished-product stability, shelf-life verification, and stricter rules for high-SPF cosmetic exclusions.
• Out-of-Scope Items (Handled Externally): Immediate chemical safety reviews (safety reviews for benzophenone et 7 active ingredients were completed in 2025; consultations on lowering maximum concentrations for homosalate et benzophenone commenced in early 2026), dedicated regulations for children’s sunscreens, and labelling instructions for novel dosage forms.

III. Crucial Reform Modules and Proposed Options

The TGA has laid out nine distinct reform modules, each weighing the status quo against more rigorous regulatory alternatives:

Module 1: SPF Testing Methodologies

• Option 1 (Status Quo): Maintain current in vivo testing protocols. Cons: Highly variable, ethical issues with human UV exposure, expensive, long testing cycles.
• Option 2 (Hybrid Framework): Allow a choice between in vivo and the newly validated ISO in vitro methods. Pros: Higher reproducibility, lower costs, ethically superior. Cons: Requires legislative rewriting; currently lacks mature water-resistance protocols.
• Option 3 (Mandatory In Vitro): Force all testing to move in vitro. Cons: Not yet recognized by AS/NZS 2604; does not adequately cover certain novel dosage forms or water-resistance claims.

Module 2: SPF Testing Laboratory Oversight

• Option 1 (Status Quo): TGA conducts basic credibility checks; no mandatory laboratory accreditation. Cons: Unreliable data, delayed enforcement.
• Option 2 (Mandatory ISO 17025): Require all testing facilities to hold ISO 17025 accreditation. Pros: Drastically improves data reliability. Cons: Very few globally compliant labs exist, creating a potential testing bottleneck for brands.

Module 3: Mechanism for Adopting Testing Standards

• Option 1 (Status Quo): Keep AS/NZS 2604 hardcoded within therapeutic goods regulations. Cons: Significant lag in adopting cutting-edge international standards.
• Option 2 (Direct Reference via Legislative Instrument): Direct reference of AS/NZS 2604 through a flexible legislative tool. Pros: Faster regulatory updates while keeping local nuances.
• Option 3 (Direct Reference of ISO Standards): Bypass local standards to directly reference international ISO standards. Pros: Instant global harmonisation. Cons: Risks decoupling regulatory synergy with New Zealand.

Module 4: Scope of the SPF Test Target (Formula vs. Finished Product)

• Option 1 (Status Quo): Allow brands to claim SPF based on a “base formula” test. Cons: Minor modifications during manufacturing can lead to the final product underperforming its SPF claim.
• Option 2 (Base Formula + Post-Change Guidelines): Allow base testing but issue non-binding guidance on when a modification requires re-testing. Cons: Lacks legal teeth to ensure compliance.
• Option 3 (Mandatory Finished Product Testing): Force pre-market finished-product testing, supplemented by mandatory shelf-life and shelf-validation testing. Pros: Absolute consumer protection. Cons: Surging R&D costs and prolonged time-to-market for brands.

Module 5: Submission of SPF Test Data

• Option 1 (Status Quo): Data is only provided if explicitly requested by the TGA during a post-market audit. Cons: Zero pre-market verification.
• Option 2 (Confidential Pre-Market Submission): Force companies to securely upload full raw testing data during ARTG listing. Pros: Enables proactive vetting while safeguarding trade secrets.
• Option 3 (Mandatory Public Disclosure): Require all raw testing data to be publicly accessible. Pros: Maximum transparency. Cons: Intellectual property exposure and potential public misinterpretation of complex lab data.

Module 6: Raw Material and Formulation Quality Control

• Option 1 (Status Quo): Rely on existing overarching standards. Cons: Fails to control batch-to-batch variables like zinc oxide particle size or UV filter purity, leading to unstable SPF values.
• Option 2 (Specific Raw Material Technical Specifications): Legislate strict specifications for UV filter purity and particulate size distribution. Pros: Stabilizes manufacturing output. Cons: Inflates production and supply chain costs.
• Option 3 (Reclassifying All Sunscreens as Registered Medicines): Move sunscreens from “Listed” to “Registered” medicines, requiring exhaustive pre-market safety, quality, and efficacy evaluations by the TGA. Cons: Upends the commercial market, causes massive backlogs, and requires an overhaul of TGA staffing infrastructure.

Module 7: SPF Label Representation

• Option 1 (Status Quo): Retain current linear numerical SPF values (e.g., SPF 30, SPF 50+). Cons: Consumers often misunderstand the non-linear relationship of UV protection (e.g., assuming SPF 50 is twice as effective as SPF 25).
• Option 2 (Contextual Explanatory Labels): Mandatory inclusion of explanatory phrases (e.g., “SPF 30 filters approximately 97% of UVB”). Pros: Clearer consumer education. Cons: Severely crowds limited label real estate.
• Option 3 (Categorical Tier Labels): Move away from numbers to broad tiers (Low / Medium / High / Very High) coupled with graphic icons. Cons: Deviates heavily from global industry standards, requiring major consumer re-education.

Module 8: Cosmetic Sunscreens with High-SPF Claims

• Option 1 (Status Quo): Tinted foundations, lip balms, and moisturizers can claim up to SPF 50+ while remaining exempt from therapeutic regulations. Cons: Regulatory double standard. Consumers often use these as primary sunscreens, exposing themselves to skin damage due to insufficient application thickness.
• Option 2 (Mandatory Warning Labels): Force secondary cosmetics to display prominent warnings like “Cosmetic Sunscreen Only – Not a Primary Sunscreen.” Pros: Mitigates risk without choking product variety.
• Option 3 (Capping the Permissible SPF Claims): Restrict secondary cosmetic exemptions to a maximum claim of SPF 15 or Low Protection. Anything higher must be registered as a therapeutic drug. Cons: Drastically restricts marketing potential and forces massive industry-wide reformulations.

Module 9: Manufacturing GMP Guidance

• Option 1 (Status Quo): Rely on generalized GMP documents. Cons: Ambiguity regarding the precise division of liabilities between brand owners and contract manufacturers.
• Option 2 (Targeted Sunscreen GMP Annex): Create a specific GMP annex outlining Critical Quality Attributes (CQAs), critical process parameters, and clear contractual split-responsibilities for third-party manufacturing. Pros: Enhances batch consistency and minimizes compliance loopholes.

IV. Other Parallel Framework Updates

1. Chemical Substance Safety: Following the completion of safety reviews for seven active sunscreen ingredients and benzophenone in late 2025, the TGA launched public consultations in early 2026 aimed at restricting maximum allowable limits for homosalate et benzophenone.
2. Children’s Sunscreens: Due to unique physiological risks, the TGA is planning a separate, dedicated consultation stream to address specific formulation limitations and safety thresholds for pediatric sunscreens.
3. Novel Delivery Mechanisms: Consultations are actively underway to replace the old TGO 92 standard with a unified framework governing application instructions and dosage labeling for aerosol, spray, and pump formats.
4. Industry Up-skilling: To ensure a smooth transition, the TGA will roll out electronic learning modules and structured webinar tracks throughout the remainder of 2026.